APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

05/16/2022 | 09:48am EDT

Item 2.02 Results of Operations and Financial Condition.

On May 16, 2022, Aprea Therapeutics, Inc., a Delaware corporation ("Aprea") and Atrin Pharmaceuticals Inc., a Delaware corporation ("Atrin") issued a joint press release announcing the issuance of Aprea's financial results for three months ended March 31, 2022 (the "Press Release"). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

Item 7.01 Regulation FD Disclosure.

The Press Release also announced the entry into a merger agreement by and among Aprea, Atrin, ATR Merger Sub I Inc., a Delaware corporation and a wholly owned subsidiary of Aprea, ATR Merger Sub II LLC, a Delaware limited liability company and wholly owned subsidiary of Aprea, and the completion of the transactions contemplated thereby. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, is furnished pursuant to Items 2.02 and 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of Aprea under the Securities Act, as amended.






Forward Looking Statements



This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding future business plans. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Aprea's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Item 9.01 - Financial Statements and Exhibits.



(d) Exhibits



Exhibit       Description
Number

  99.1          Joint Press Release of Aprea and Atrin, dated May 16, 2022.

Exhibit 104   Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses

All news about APREA THERAPEUTICS, INC.
05/25Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold R..
MT
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021
Capitalization 18,7 M 18,7 M -
EV / Sales 2021
EV / Sales 2022 -
Nbr of Employees -
Free-Float 90,2%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,81 $
Average target price 1,00 $
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman & Chief Executive Officer
Oren Gilad President & Director
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-71.78%19
MODERNA, INC.-44.02%57 385
IQVIA HOLDINGS INC.-24.79%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.15.44%33 010
CELLTRION, INC.-11.87%18 371